MHLW Orders Additional Adverse Effect To Bayer’s Nexavar
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare has ordered Bayer Healthcare to add a serious adverse effect to cancer drug Nexavar (sorafenib) upon receiving reports that after taking the drug, four patients have developed interstitial pneumonia, and among them two died of the disease. Approved by the MHLW in April 2008, sorafenib was launched to the market with an indication to treat progressive kidney cell cancer. There are 2,000 patients who are taking the drug in Japan. (Click here for more - Japanese language
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.